Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 42 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]
2. Cita con resumen
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]
3. Cita con resumen
Anónimo. Éribuline et liposarcome inopérable réfractaire ou en rechute. Prescrire 2017;37:416-7. [Ref.ID 102000]
4. Cita con resumen
Anónimo. Aprépitant chez les enfants. Prescrire 2017;37:5-7. [Ref.ID 101361]
5.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
6. Cita con resumen
Hosseinjani H, Moghaddas A, Khalili H. N-acetylcysteine for the prevention of non-constrast media agent-induced kidney injury: from preclinical data to clinical evidence. Eur J Clin Pharmacol 2013;69:1375-90. [Ref.ID 95850]
7. Cita con resumen
van der Pal HJH, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, Oldenburger F, Koning CCE, van Leeuwen FE, Kremer LCM. Cardiac function in 5-year survivors of childhood cancer. A long-term follow-up study. Arch Intern Med 2010;170:1247-55. [Ref.ID 88933]
8.
Liamis G, Milionis HJ, Elisaf M. Pharmacologically-induced metabolic acidosis: a review. Drug Saf 2010;33:371-91. [Ref.ID 88433]
9. Cita con resumen
Anónimo. Insuffisances rénales d'origine médicamenteuse. Prescrire 2009;29:506-10. [Ref.ID 86213]
11.
Brain EGC, Rezai K, Lokiec F, Gutiérrez M, Urien S. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n=1 randomized study. Br J Clin Pharmacol 2008;65:607-10. [Ref.ID 82511]
12. Cita con resumen
Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72. [Ref.ID 80043]
13. Cita con resumen
Anónimo. 5HT3-receptor antagonists as antiemetics in cancer. Drug Ther Bull 2005;43:57-62. [Ref.ID 74565]
14.Tiene citas relacionadas
Argiris A, Schiller JH. Can current treatments for advanced non-small-cell lung cancer be improved?. JAMA 2004;292:499-500. [Ref.ID 70883]
15.Tiene citas relacionadas Cita con resumen
Delbado C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon J-P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. A meta-analysis. JAMA 2004;292:470-84. [Ref.ID 70882]
17. Cita con resumen
Anónimo. CPMP evenly split on Yondelis rejection appeal. Scrip 2004;2915:26. [Ref.ID 68654]
18.Tiene citas relacionadas
Wittes RE. Therapies for cancer in children - past successes, future challenges. N Engl J Med 2003;348:747-9. [Ref.ID 65096]
19.Tiene citas relacionadas
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard D J, Gebhardt MC, Dickman PS, Perlman E J, Meyers PA, Donaldson SS, Moore S, Rausen A R, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701. [Ref.ID 65089]
20.
Verstappen CCP, Heimans JJ, Hoekman K, Postma T J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003;63:1549-63. [Ref.ID 64215]
Seleccionar todas
 
 1 a 20 de 42 siguiente >>